Radiopharm Theranostics reported a A$56.3 million comprehensive loss for fiscal 2026, with operating cash outflows rising to A$52.8 million and cash falling to A$4.1 million. The company says further funding is required, while auditors flag a material uncertainty over its ability to continue as a going concern.
- A$56.3 million total comprehensive loss
- A$52.8 million operating cash outflow
- A$4.1 million cash at 30 June 2026
- Research and development spending rose to A$50.0 million
- Post-year-end capital raising and further dilution
Cash position triggers going concern warning
Radiopharm Theranostics Limited (ASX:RAD; Nasdaq:RADX) ended fiscal 2026 with just A$4.1 million in cash after burning A$52.8 million on operations. The clinical-stage radiopharmaceutical company reported a total comprehensive loss of A$56.3 million, up from A$37.9 million a year earlier, and its auditors highlighted a material uncertainty that may cast significant doubt on its ability to continue as a going concern.
Management says its current forecasts support continued operations and clinical development for at least the next 12 months, but that conclusion depends on raising additional capital and managing expenditure. Radiopharm said it may delay or reduce operating activities if necessary. The filing also makes clear that the business has no approved products and no product revenue, leaving equity funding, collaboration receipts and the Australian research and development tax incentive as its practical sources of liquidity.
The balance sheet contains a sizeable A$15.9 million receivable from the Australian Taxation Office for the R&D tax incentive, but that is not the same as cash available to fund near-term trials. At 30 June, Radiopharm also carried A$25.8 million of other financial liabilities, much of it linked to milestone obligations under licensing agreements.
Clinical spending accelerates while losses deepen
Research and development expenditure jumped 82% to A$50.0 million, driven by increased spending on the NanoMab platform, Radiopharm Ventures, the PSA-mAb programme and Pivalate. General and administrative costs rose more modestly to A$16.2 million, while revenue from contracts with customers fell to A$2.8 million from A$3.6 million as reimbursements associated with the Lantheus development programme declined.
The filing points to several clinical milestones in the pipeline. RAD101, the brain-metastases imaging candidate, completed a 30-patient Phase IIb trial with 93% concordance against MRI, while an interim analysis reported sensitivity of 86% in 12 of 14 patients. Radiopharm anticipates a multi-country Phase III registrational study in the final quarter of calendar 2026, with Siemens Healthineers expected to manufacture and distribute doses for the programme. Those results are encouraging, but the dataset remains early-stage and the next trial still depends on regulatory, funding and execution milestones.
Other programmes remain earlier in development. RAD202 is in Phase I testing for HER2-positive breast and gastric cancer, RAD204 is in Phase I testing for non-small cell lung cancer, RAD301’s diagnostic trial had dosed eight of nine intended patients, and RAD402 began its first-in-human Phase I study in prostate cancer. Radiopharm Ventures, in which the company holds an 87.5% interest, also dosed the first patient in its RV-01 Phase I/IIa trial targeting B7-H3-expressing solid tumours.
Capital raising becomes the next clinical milestone
Radiopharm’s funding requirement is already visible in its capital structure. The company issued A$35.4 million of equity during fiscal 2026, taking ordinary shares on issue to 3.54 billion. A further A$12.5 million institutional offer and a US direct registration offering were announced after year-end, while the Share Purchase Plan raised another A$3 million. The company also has an unused US$9.3 million ATM facility available through Leerink Partners.
Existing holders face dilution risk on several fronts. The annual report lists approximately 2.5 billion options over ordinary shares, alongside further potential share settlements tied to licensing milestones. Radiopharm’s disclosures also identify up to US$123.5 million of potential Diaprost milestones, US$90 million under the TRIMT agreement and US$72.28 million linked to MD Anderson’s licensed assets, although those amounts depend on future development events and are not all currently payable.
Radiopharm fully impaired the Pharma15 asset during the year after determining that no funding was committed to the programme for the foreseeable future, and returned the NeoIndicate asset to the university. The sharper question now is whether the company can convert its most advanced clinical signals into regulatory progress before its cash position again forces shareholders to finance the gap.
Bottom Line?
The pipeline has produced meaningful clinical signals, but Radiopharm’s next value test may be financial: securing enough capital to reach the next trial milestones without overwhelming existing shareholders.
Questions in the middle?
- How much of the announced institutional and US offering will ultimately be completed, and on what terms?
- Can RAD101 move into its planned Phase III programme before another material funding requirement emerges?
- How will the company manage its large option pool and milestone-linked share obligations as development advances?